Olanzapine

Jump to

US, Russia & API boost Dr Reddy's as busy year looms

GV Prasad VC & CEO, Dr Reddy Laboratories explains to CNBC-TV18 that the reason for company‘s good performance for the quarter is the robust growth in the US, Russia and the API business
Orchid, Aurobindo get nod to sell Schizophrenia drug copy

Orchid Chemicals and Pharmaceuticals and rival Aurobindo Pharma have received US Food and Drug Administration (FDA) approval for their abbreviated new drug application (ANDA) for Olanzapine tablets, a generic version of Eli Lilly's Zyprexa tablets, in various strengths.
Dr Reddy's Q3 beats street; cons net jumps 88% YoY

Dr Reddy's Laboratories reported a better-than-expected 88% year-on-year rise in third quarter net profit at Rs 513 crore, helped by new high margin drug launches and foreign exchange gains.
Business from Russia, US markets add to Dr Reddy's coffers

G V Prasad, VC & CEO, Dr Reddy's Laboratories tells CNBC-TV18 that North America, Russia and the Pharmaceuticals Services and Active Ingredients (PSAI) segment led to the stupendous growth in the business.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Olanzapine

US, Russia & API boost Dr Reddy's as busy year looms

Orchid, Aurobindo get nod to sell Schizophrenia drug copy

Dr Reddy's Q3 beats street; cons net jumps 88% YoY

Business from Russia, US markets add to Dr Reddy's coffers